AstraZeneca is paying insitro $40 million upfront to find liver and heart drug targets
Insitro is eligible for up to about $1.46 billion in milestone payments, plus single-digit royalties on global sales
We haven't written up this one. Quartz has the full story — the link below goes straight to it.